Drugs / TAC-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05399654 | Jun 2022 → Jan 2026 overdue | — | Tallac Therapeutics | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2025-10-20 | Tallac Therapeutics | Regulatory FDA Grants Fast Track Designation to TAC-001 tallactherapeutics.com ↗
Tallac Therapeutics announced today that the U.S. Food and Drug Administration has granted Fast Track designation to TAC-001 for the treatment of previously treated, locally advanced unresectable or metastatic cholangiocarcinoma. |
| 2024-04-10 | Tallac Therapeutics | Results Tallac Therapeutics Presents New Preclinical Data on TAC-001 in Combination with Cancer Vaccines at the 2024 Annual Meeting of the American Association for Cancer Research (AACR) tallactherapeutics.com ↗
Tallac Therapeutics, Inc., a privately held clinical stage biopharmaceutical company pioneering the discovery and development of novel antibody-oligonucleotide conjugates, today announced the presentation of preclinical data demonstrating TAC-001 potentiates cancer vaccine efficacy and rejuvenates vaccine responses. |
| 2023-11-03 | Tallac Therapeutics | Results Tallac Presents First Clinical Data for TAC-001 at SITC 2023 tallactherapeutics.com ↗
These TAC-001 clinical data provide evidence that systemic administration of a TLR9 immune agonist targeting and activating B cells is generally well tolerated and induces immune activation consistent with preclinical studies. |
| 2022-05-19 | Tallac Therapeutics | Regulatory Tallac Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for TAC-001, a First-in-Class Toll-like Receptor 9 (TLR9) Agonist Antibody Conjugate for Patients with Advanced Solid Tumors tallactherapeutics.com ↗ |
| 2021-04-12 | Tallac Therapeutics | Results Tallac AACR 2021 Presentation tallactherapeutics.com ↗
In vivo, TAC-001 demonstrated robust, curative and durable single agent anti-tumor activity in checkpoint inhibitor resistant and refractory tumor models. |
| 2021-03-12 | Tallac Therapeutics | Results AACR 2021 presentation on preclinical data for TAC-001 tallactherapeutics.com ↗
TAC-001, a toll-like receptor 9 (TLR9) agonist antibody conjugate targeting B cells, promotes anti-tumor immunity and favorable safety profile following systemic administration in preclinical models |
All press releases naming this drug 7 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAC-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05399654 ↗ |
| Action | Activate | “Toll-like Receptor Agonist” NCT05399654 ↗ |
| Modality | Other / unclassified | “TAC-001 is a Toll-like Receptor Agonist Antibody Conjugate (TRAAC)” NCT05399654 ↗ |
| Route | Intravenous | “TAC-001 administered intravenously.” NCT05399654 ↗ |